Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS – Research Report), Globus Medical (GMED – Research Report) and Ramsay Health Care (RMSYF – Research Report).
Confident Investing Starts Here:
Pyxis Oncology (PYXS)
In a report issued on May 15, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $8.00. The company's shares closed last Monday at $1.23, close to its 52-week low of $0.99.
According to TipRanks.com, Timashev is a 1-star analyst with an average return of -0.5% and a 32.8% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Design Therapeutics.
Currently, the analyst consensus on Pyxis Oncology is a Strong Buy with an average price target of $6.83, representing a 483.8% upside. In a report issued on May 16, Leerink Partners also maintained a Buy rating on the stock with a $7.00 price target.
Globus Medical (GMED)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical on May 15 and set a price target of $95.00. The company's shares closed last Monday at $61.05.
According to TipRanks.com, Chadha is a 2-star analyst with an average return of 0.5% and a 48.6% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Tandem Diabetes Care.
Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $87.38, implying a 44.6% upside from current levels. In a report issued on May 8, Morgan Stanley also maintained a Buy rating on the stock with a $100.00 price target.
Ramsay Health Care (RMSYF)
RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Ramsay Health Care on May 15 and set a price target of A$41.00. The company's shares closed last Thursday at $22.00.
According to TipRanks.com, Wong-Pan is ranked #7861 out of 9558 analysts.
Ramsay Health Care has an analyst consensus of Hold, with a price target consensus of $25.32, implying an 11.2% upside from current levels. In a report issued on May 5, Morgan Stanley also maintained a Hold rating on the stock with a A$37.20 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
2 Growth Stocks to Add to Your Roster and 1 to Brush Off
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle. The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. On that note, here are two growth stocks where the best is yet to come and one climbing an uphill battle. One-Year Revenue Growth: +15.7% Founded in 1915, Fox (NASDAQ:FOXA) is a diversified media company, operating prominent cable news, television broadcasting, and digital media platforms. Why Should You Dump FOXA? Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 3.9% over the last two years was below our standards for the consumer discretionary sector Forecasted revenue decline of 4.3% for the upcoming 12 months implies demand will fall off a cliff FOX's stock price of $53.50 implies a valuation ratio of 13.6x forward P/E. If you're considering FOXA for your portfolio, see our FREE research report to learn more. One-Year Revenue Growth: +27.4% Originally a metal-working shop supporting local petrochemical facilities, Powell (NYSE:POWL) has grown from a small Houston manufacturer to a global provider of electrical systems. Why Could POWL Be a Winner? Impressive 34.8% annual revenue growth over the last two years indicates it's winning market share this cycle Operating profits and efficiency rose over the last five years as it benefited from some fixed cost leverage Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 209% annually At $181 per share, Powell trades at 12.3x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it's free. One-Year Revenue Growth: +32.3% With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures. Why Do We Like GMED? Average constant currency growth of 61.4% over the past two years demonstrates its ability to grow internationally despite currency fluctuations Revenue outlook for the upcoming 12 months is outstanding and shows it's on track to gain market share Earnings growth has trumped its peers over the last five years as its EPS has compounded at 13.8% annually Globus Medical is trading at $59.20 per share, or 16.8x forward P/E. Is now a good time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Business Insider
3 days ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Performance Shipping (PSHG) and Sterling Construction (STRL)
There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Performance Shipping (PSHG – Research Report) and Sterling Construction (STRL – Research Report) with bullish sentiments. Confident Investing Starts Here: Performance Shipping (PSHG) In a report issued on May 30, Tate Sullivan from Maxim Group reiterated a Buy rating on Performance Shipping, with a price target of $5.00. The company's shares closed last Tuesday at $1.60, close to its 52-week low of $1.48. According to Sullivan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.9% and a 38.7% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as United Maritime Corp., Seanergy Maritime, and BWX Technologies. The the analyst consensus on Performance Shipping is currently a Hold rating. William Blair analyst Louie DiPalma maintained a Buy rating on Sterling Construction today. The company's shares closed last Tuesday at $194.23, close to its 52-week high of $206.07. According to DiPalma has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 60.6% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Science Applications, and BigBearai Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sterling Construction with a $205.00 average price target.
Business Insider
3 days ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
